NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $41.83, a high estimate of $50.00, and a low estimate of $30.00. This current ...

Nimblemind.ai – a healthcare startup in Chicago dedicated to offering a faster and safer way to structure, label, and manage ...

The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion five-year, interest-only fixed rate mortgage financing with a weighted-average ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced a multi-year partnership with Google Cloud to accelerate cloud transformation ...

Vertex reported quarterly earnings of 15 cents per share which beat the analyst consensus estimate of 14 cents per share. The ...

It’s a fair question — and one genuinely difficult to answer about a president who thrives on outrage and leans heavily into ...

We recently published 10 Stocks Taking the Worst Hit. Vertex Inc. (NASDAQ:VERX) is one of the worst-performing stocks on ...

Mars partners with biotech firm Pairwise to develop climate-resilient cacao using CRISPR technology, aiming to safeguard the ...

Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...

Discover how dragonflies and damselflies mate, transform through their life cycle, and why bluet species are unique, with ...